A Study to Evaluate LTI-01 in Patients With Infected, Non-draining Pleural Effusions
Recruiting in Palo Alto (17 mi)
+32 other locations
Age: 18+
Sex: Any
Travel: May be covered
Time Reimbursement: Varies
Trial Phase: Phase 2
Waitlist Available
Sponsor: Lung Therapeutics, Inc
Prior Safety Data
Trial Summary
What is the purpose of this trial?The LTI-01-2001 study is a double-blind, placebo-controlled, Phase 2 study to evaluate LTI-01 (single-chain urokinase plasminogen activator, scuPA) in patients with infected, non-draining pleural effusions.
Eligibility Criteria
Participant Groups
4Treatment groups
Experimental Treatment
Placebo Group
Group I: 800,000 U LTI-01Experimental Treatment1 Intervention
800,000 U LTI-01 qd x 3 days administered intrapleurally
Group II: 400,000 U LTI-01Experimental Treatment1 Intervention
400,000 U LTI-01 once a day (qd) x 3 days administered intrapleurally
Group III: 1,200,000 U LTI-01Experimental Treatment1 Intervention
1,200,000 U LTI-01 qd x 3 days administered intrapleurally
Group IV: PlaceboPlacebo Group1 Intervention
placebo (normal saline) 6ml qd x 3 days administered intrapleurally
Find A Clinic Near You
Research locations nearbySelect from list below to view details:
The Ohio State UniversityColumbus, OH
The Pennsylvania State UniversityHershey, PA
North Shore - Long Island Jewish Medical CenterQueens, NY
University of PennsylvaniaPhiladelphia, PA
More Trial Locations
Loading ...
Who is running the clinical trial?
Lung Therapeutics, IncLead Sponsor